<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1849">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04634370</url>
  </required_header>
  <id_info>
    <org_study_id>20200210</org_study_id>
    <nct_id>NCT04634370</nct_id>
  </id_info>
  <brief_title>Fase I Clinical Trial on NK Cells for COVID-19</brief_title>
  <official_title>Fase I Clinical Trial on Natural Killer Cells for COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronavirus Disease 2019 (COVID-19) is spreading worldwide and has become a public health&#xD;
      emergency of major international concern. Currently, no specific drugs or vaccines are&#xD;
      available.&#xD;
&#xD;
      This study aims to investigate the safety and efficacy of intravenous infusion of natural&#xD;
      killer cells patients with COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In March 2020, the World Health Organization secreted COVID-19 as a pandemic. Although most&#xD;
      infected individuals can develop effective immunity, the population at risk (elderly, obese&#xD;
      and individual with comorbidities) develop a rapid and frequently fatal disease, with severe&#xD;
      acute respiratory syndrome, cytokine storm and coagulopathies; for those who recover, severe&#xD;
      pulmonary sequels are frequently observed. We propose a phase I clinical trial to test safety&#xD;
      and feasibility of NK cells adoptive immunotherapy for COVID-19. Natural Killer cells are&#xD;
      innate granular lymphocytes able to rapidly recognize and kill, without previous exposition,&#xD;
      altered cells; it is widely recognized as immune effectors specialized in lysing virus&#xD;
      infected cells releasing antigens and activating cytokines to antigen presenting cells and,&#xD;
      by doing so, stimulating effective adaptive immunity. We hypothesize that the early infusion&#xD;
      of highly activated NK cells will activate adaptive immune effectors preventing the severe&#xD;
      clinical evolution of COVID-19 infection. Adoptive NK cell immunotherapy for severe virus&#xD;
      infections is innovative. Our proposition is in line with the Brazilian Public Health system&#xD;
      purposes, which is to offer secure and effective therapies for all COVID-19 infected&#xD;
      individuals. Upon proving NK cell immunotherapy effectiveness for serious virus infections,&#xD;
      we can evolve to test this strategy for common viruses that cause epidemics and endemics such&#xD;
      as the ones caused by Dengue, Zika, Chikungunya, C and B hepatitis and HIV.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>30 days</time_frame>
    <description>Assessment of Overall survival at 30 days post intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes on inflammatory C-reactive protein</measure>
    <time_frame>60 days</time_frame>
    <description>To assess the anti-inflammatory effect of the proposed treatment with assessment of the levels of C-reactive protein (mg/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospital stay</measure>
    <time_frame>60 days</time_frame>
    <description>days of the patients in hospital</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxygenation index (PaO2/FiO2)</measure>
    <time_frame>60 days</time_frame>
    <description>Evaluation of functional respiratory changes: PaO2 / FiO2 ratio</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in Liao's score (2020)</measure>
    <time_frame>60 days</time_frame>
    <description>Improvement in Liao's score (2020)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiological improvement</measure>
    <time_frame>60 days</time_frame>
    <description>Computed tomography Chest assesment will be done to assess improvement in radiological findings of COVID-19</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Covid19</condition>
  <condition>Sars-cov 2</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive on dose of intravenous natural killer cell in following levels:&#xD;
Level 1 : 1x106 cells/kg body weight (patients 1 to 3) Level 2: 5x106 cells/kg body weight (patients 4 to 6) Level 3: 1x107 cells/kg body weight (patients 7 to 24)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Natural Killer Cells infusion</intervention_name>
    <description>Each patient will receive on dose of intravenous natural killer cell in following levels:&#xD;
Level 1 : 1x106 cells/kg body weight (patients 1 to 3) Level 2: 5x106 cells/kg body weight (patients 4 to 6) Level 3: 1x107 cells/kg body weight (patients 7 to 24)</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Laboratory confirmation of COVID19 infection by reverse-transcription polymerase chain&#xD;
             reaction (RT-PCR);&#xD;
&#xD;
          -  The patient or legal donor agrees to participate in the study and signs the informed&#xD;
             consent;&#xD;
&#xD;
          -  Patients with white or yellow criteria according to the score proposed by Liao et al&#xD;
             (2020).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with pregnancy, are planning to become pregnant or breastfeeding;&#xD;
&#xD;
          -  Patients with malignant blood-borne diseases such as HIV or syphilis;&#xD;
&#xD;
          -  Not consenting for clinical trial;&#xD;
&#xD;
          -  Patients with other than white or yellow criteria according to the score proposed by&#xD;
             Liao et al (2020).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucia Silla, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clinicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lucia Silla, MD, PhD</last_name>
    <phone>55 51 33598371</phone>
    <email>lsilla@hcpa.edu.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annelise Pezzi, PhD</last_name>
    <email>annepezzi@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Lucia Silla, Md, PhD</last_name>
      <phone>555133598850</phone>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Natural Killer Cells</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Sars-CoV2</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

